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This editorial refers to ‘Cardiac autonomic disturbances in
patients with vasovagal syndrome: comparison between
iodine-123-metaiodobenzylguanidine myocardial scintig-
raphy and heart rate variability’ by G. Kochiadakis et al.,
on page 1352
In this issue of the Journal, Kochiadakis and co-workers from
Heraklion University Hospital in Athens report on autonomic
regulation in patients with vasovagal syncope (VVS) diagnosed
with tilt table testing.1 They measured heart rate variability
(HRV) and assessed cardiac sympathetic innervation using 123-I-
meta-iodobenzylguanidine (MIBG) scintigraphy. The main finding
of this study was that adrenergic cardiac innervation showed
defects in the left ventricle in patients with VVS. This finding was
not associated with the type of response (cardioinhibitory or vaso-
depressor) during tilt table testing. However, the study critics may
object that the infrequent blood pressure measurements rather
than continuous non-invasive blood pressure measurement
during tilt table testing did not allow the accurate classification
of the response. In contrast to this finding, HRV, as a marker of
the resulting efferent vasomotor activity at the level of the sinus
node, did not show any significant difference between patients
and control subjects when measured the day after the tilt test.
Thus, on the one hand, the authors report an interesting new
finding pointing to a potential pathoanatomical substrate involved
in the complex mechanism of VVS, whereas on the other hand a
well-known method, claimed to monitor the sympathovagal activ-
ity, fails to show any difference.
There has been a great enthusiasm about HRV as an easily ob-
tainable and simple non-invasive measure of the influence of the
autonomic nervous system after the early paper by Akselrod
et al.2 The method was applied to short-term recordings in the la-
boratory as well as ambulatory 24 h electrocardiographic (ECG)
recordings, and algorithms for computing HRV in both the time
domain and power spectral analysis have soon become commer-
cially available. This new tool was used to investigate the efferent
autonomic control of the sinus node in various conditions and
to predict future arrhythmic events in diseased hearts. Despite
the availability of ECGs and many attempts in prospective
studies, there has not been any clinical breakthrough for
HRV-derived indices to have an independent prognostic value.3
Regarding the applicability of HRV as a physiological measure of
cardiac autonomic control, it is characteristic that the authors
cite earlier studies from 19944 and 1986.5 These publications
refer to a different method of quantifying the HRV than that uti-
lized in the present study, namely power spectral analysis. It
would have been interesting to correlate the sequence of the car-
diovascular response and the changes in HRV evaluated with
power spectral analysis during the tilt table test, instead of time-
domain analysis the day after the tilt test. In general, there
appears nothing new in the literature, including the current
paper, on HRV and the mechanisms of VVS.
It is, therefore, encouraging that Kochiadakis et al. attempted to
find new clues to the VVS puzzle. With the use of MIBG, they have
demonstrated that patients with VVS have an altered pattern of ad-
renergic cardiac innervation, suggesting persistent dysfunction of
myocardial adrenergic innervation. Where HRV has shown only
temporary changes during tilt in VVS patients,6 but not in
control state,1 MIBG shows significant changes and this is
present even in the normal state. This finding implies that VVS is
not only a functional disorder but may have a pathoanatomical sub-
strate. However, other aspects need to be addressed as bradycar-
dia is not the only feature of VVS; control of blood pressure
regulation, humoral factors, neural triggers, etc. are all of import-
ance when trying to entangle the wide range of cardiovascular
responses in VVS. Furthermore, it is important to appreciate that
it may be a crude generalization to reduce all neurally mediated
reflex syndromes to sharing the common pathway of events
leading to bradycardia, hypotension, and loss of consciousness. Al-
though the present finding needs to be reproduced and put into
context of the complex mechanism involved in VVS, it represents
a step forward in our understanding of VVS.
The European Society of Cardiology (ESC) guidelines from
20097 on diagnosis and management of patients with syncope is
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an excellent clinical tool, and it already has been followed by several
clinical studies8,9 on diagnosing and stratifying patients with syncope.
Implementation of these guidelines and the establishment of dedi-
cated syncope facilities are essential for the management of patients
with this syndrome, whose underlying causes range from the benign
isolated VVS to malignant arrhythmias.
In spite of advances in diagnosis and risk stratification of patients
with syncope, treatment of VVS is often difficult and challenging,
but a better understanding of the condition and precipitating
factors may lead to better treatment. In this regard, the contribu-
tion by Kochiadakis and co-workers is welcome.
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Superior vena cava obstruction due to pacemaker leads
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A 45-year-old woman was referred for a pulse generator change with
insertion of a new ventricular lead. Given a wire would not advance
into the right atrium, a venogram was performed. Injection of con-
trast demonstrated complete occlusion of the distal superior vena
cava with extensive dilation of the hemiazygous system and collater-
alization into the inferior vena cava. The patient had no symptoms in-
dicative of obstruction. In the coming years, this ‘silent’ complication
will gain increasing attention as the number of patients requiring new
leads will increase with ageing of the population, expansion of implant
guidelines, and ongoing recalls.
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